FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2556108575> ?p ?o ?g. }

• W2556108575 endingPage "140" @default.
• W2556108575 startingPage "136" @default.
• W2556108575 abstract "•The cumulative OS rates at 1 and 2 years were 95.45% and 89.09%. •The cumulative 1 and 2-year PFS rates were 80.90% and 62.73%. •For BCLC class C patients (n=60), cumulative 1 and 2-year OS were 89.09% and 74.54%. •Child-Pugh score and BCLC class were independent risk factors for OS. •Number of tumour nodules was an independent risk factor for reoccurrence. Aim To evaluate the treatment efficacy and potential complications of computed tomography (CT)-guided microwave ablation for primary hepatocellular carcinoma (HCC). Materials and methods Data were collected and analysed from 220 HCC patients treated with CT-guided microwave ablation and followed up for 2 years. Independent risk factors for overall survival and progression-free survival (PFS) were analysed. Results Among all cases followed, the cumulative overall survival rates at 1 and 2 years were 95.45% and 89.09%. The cumulative 1- and 2-year PFS rates were 80.90% and 62.73%. For patients with Barcelona Clinic Liver Cancer (BCLC) class C (n=60), the cumulative 1- and 2-year overall survival rates were 89.09% and 74.54%. In this group, patients with tumour invasion of blood vessels or tumour-related symptoms suffered a worse overall survival compared to those without (p=0.011). No fatal complications were observed. Child–Pugh score (p=0.030) and BCLC class (p=0.012) were independent risk factors for overall survival. The number of tumour nodules was an independent risk factor for reoccurrence. Conclusion CT-guided percutaneous microwave ablation could be an effective and safe treatment option for HCC patients. To evaluate the treatment efficacy and potential complications of computed tomography (CT)-guided microwave ablation for primary hepatocellular carcinoma (HCC). Data were collected and analysed from 220 HCC patients treated with CT-guided microwave ablation and followed up for 2 years. Independent risk factors for overall survival and progression-free survival (PFS) were analysed. Among all cases followed, the cumulative overall survival rates at 1 and 2 years were 95.45% and 89.09%. The cumulative 1- and 2-year PFS rates were 80.90% and 62.73%. For patients with Barcelona Clinic Liver Cancer (BCLC) class C (n=60), the cumulative 1- and 2-year overall survival rates were 89.09% and 74.54%. In this group, patients with tumour invasion of blood vessels or tumour-related symptoms suffered a worse overall survival compared to those without (p=0.011). No fatal complications were observed. Child–Pugh score (p=0.030) and BCLC class (p=0.012) were independent risk factors for overall survival. The number of tumour nodules was an independent risk factor for reoccurrence. CT-guided percutaneous microwave ablation could be an effective and safe treatment option for HCC patients." @default.
• W2556108575 created "2016-11-30" @default.
• W2556108575 creator A5008953620 @default.
• W2556108575 creator A5013963500 @default.
• W2556108575 creator A5040351896 @default.
• W2556108575 creator A5044811395 @default.
• W2556108575 creator A5066532132 @default.
• W2556108575 date "2017-02-01" @default.
• W2556108575 modified "2023-09-30" @default.
• W2556108575 title "Treatment efficacy of CT-guided percutaneous microwave ablation for primary hepatocellular carcinoma" @default.
• W2556108575 cites W1744726727 @default.
• W2556108575 cites W1820070451 @default.
• W2556108575 cites W1974901379 @default.
• W2556108575 cites W1980571899 @default.
• W2556108575 cites W2002906231 @default.
• W2556108575 cites W2017206508 @default.
• W2556108575 cites W2053526872 @default.
• W2556108575 cites W2117283868 @default.
• W2556108575 cites W2131357269 @default.
• W2556108575 cites W2161515064 @default.
• W2556108575 cites W2163486683 @default.
• W2556108575 cites W2188916028 @default.
• W2556108575 cites W2238535152 @default.
• W2556108575 cites W2308063030 @default.
• W2556108575 cites W2329969946 @default.
• W2556108575 cites W2401804267 @default.
• W2556108575 cites W2917837889 @default.
• W2556108575 cites W4211105405 @default.
• W2556108575 cites W4245784696 @default.
• W2556108575 doi "https://doi.org/10.1016/j.crad.2016.10.022" @default.
• W2556108575 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27890422" @default.
• W2556108575 hasPublicationYear "2017" @default.
• W2556108575 type Work @default.
• W2556108575 sameAs 2556108575 @default.
• W2556108575 citedByCount "11" @default.
• W2556108575 countsByYear W25561085752018 @default.
• W2556108575 countsByYear W25561085752019 @default.
• W2556108575 countsByYear W25561085752021 @default.
• W2556108575 countsByYear W25561085752022 @default.
• W2556108575 countsByYear W25561085752023 @default.
• W2556108575 crossrefType "journal-article" @default.
• W2556108575 hasAuthorship W2556108575A5008953620 @default.
• W2556108575 hasAuthorship W2556108575A5013963500 @default.
• W2556108575 hasAuthorship W2556108575A5040351896 @default.
• W2556108575 hasAuthorship W2556108575A5044811395 @default.
• W2556108575 hasAuthorship W2556108575A5066532132 @default.
• W2556108575 hasConcept C126322002 @default.
• W2556108575 hasConcept C141071460 @default.
• W2556108575 hasConcept C151032500 @default.
• W2556108575 hasConcept C2776231280 @default.
• W2556108575 hasConcept C2776283816 @default.
• W2556108575 hasConcept C2778014663 @default.
• W2556108575 hasConcept C2778019345 @default.
• W2556108575 hasConcept C2780813298 @default.
• W2556108575 hasConcept C2994039464 @default.
• W2556108575 hasConcept C50440223 @default.
• W2556108575 hasConcept C71924100 @default.
• W2556108575 hasConcept C90924648 @default.
• W2556108575 hasConceptScore W2556108575C126322002 @default.
• W2556108575 hasConceptScore W2556108575C141071460 @default.
• W2556108575 hasConceptScore W2556108575C151032500 @default.
• W2556108575 hasConceptScore W2556108575C2776231280 @default.
• W2556108575 hasConceptScore W2556108575C2776283816 @default.
• W2556108575 hasConceptScore W2556108575C2778014663 @default.
• W2556108575 hasConceptScore W2556108575C2778019345 @default.
• W2556108575 hasConceptScore W2556108575C2780813298 @default.
• W2556108575 hasConceptScore W2556108575C2994039464 @default.
• W2556108575 hasConceptScore W2556108575C50440223 @default.
• W2556108575 hasConceptScore W2556108575C71924100 @default.
• W2556108575 hasConceptScore W2556108575C90924648 @default.
• W2556108575 hasFunder F4320334977 @default.
• W2556108575 hasIssue "2" @default.
• W2556108575 hasLocation W25561085751 @default.
• W2556108575 hasLocation W25561085752 @default.
• W2556108575 hasOpenAccess W2556108575 @default.
• W2556108575 hasPrimaryLocation W25561085751 @default.
• W2556108575 hasRelatedWork W2312248965 @default.
• W2556108575 hasRelatedWork W2360814204 @default.
• W2556108575 hasRelatedWork W2370312681 @default.
• W2556108575 hasRelatedWork W2377894786 @default.
• W2556108575 hasRelatedWork W2431094718 @default.
• W2556108575 hasRelatedWork W2790079616 @default.
• W2556108575 hasRelatedWork W3029432525 @default.
• W2556108575 hasRelatedWork W3032550575 @default.
• W2556108575 hasRelatedWork W3216077230 @default.
• W2556108575 hasRelatedWork W4251483940 @default.
• W2556108575 hasVolume "72" @default.
• W2556108575 isParatext "false" @default.
• W2556108575 isRetracted "false" @default.
• W2556108575 magId "2556108575" @default.
• W2556108575 workType "article" @default.